NASDAQ:CDTX Cidara Therapeutics (CDTX) Stock Price, News & Analysis → This consistently signaled gains of 453%... 610%... and even 1036%... (From Insiders Exposed) (Ad) Free CDTX Stock Alerts $0.84 +0.10 (+13.48%) (As of 03/27/2024 ET) Add Compare Share Share Today's Range$0.74▼$0.8550-Day Range$0.64▼$0.8452-Week Range$0.59▼$1.48Volume1.44 million shsAverage Volume524,240 shsMarket Capitalization$76.31 millionP/E RatioN/ADividend YieldN/APrice Target$4.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Cidara Therapeutics alerts: Email Address Cidara Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside454.2% Upside$4.67 Price TargetShort InterestHealthy0.20% of Shares Sold ShortDividend StrengthN/ASustainability-0.85Upright™ Environmental ScoreNews Sentiment0.20Based on 2 Articles This WeekInsider TradingSelling Shares$40,490 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($0.28) to ($0.65) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.35 out of 5 starsMedical Sector133rd out of 939 stocksBiological Products, Except Diagnostic Industry17th out of 151 stocks 3.5 Analyst's Opinion Consensus RatingCidara Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.67, Cidara Therapeutics has a forecasted upside of 454.2% from its current price of $0.84.Amount of Analyst CoverageCidara Therapeutics has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.20% of the outstanding shares of Cidara Therapeutics have been sold short.Short Interest Ratio / Days to CoverCidara Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cidara Therapeutics has recently decreased by 18.93%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCidara Therapeutics does not currently pay a dividend.Dividend GrowthCidara Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCidara Therapeutics has received a 72.74% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for infectious diseases", "Preclinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Cidara Therapeutics is -0.85. Previous Next 2.9 News and Social Media Coverage News SentimentCidara Therapeutics has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Cidara Therapeutics this week, compared to 1 article on an average week.Search Interest13 people have searched for CDTX on MarketBeat in the last 30 days. This is an increase of 225% compared to the previous 30 days.MarketBeat Follows4 people have added Cidara Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cidara Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $40,490.00 in company stock.Percentage Held by InsidersOnly 7.43% of the stock of Cidara Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 35.82% of the stock of Cidara Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Cidara Therapeutics are expected to decrease in the coming year, from ($0.28) to ($0.65) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cidara Therapeutics is -2.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cidara Therapeutics is -2.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIWarning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…Watch the presentation here About Cidara Therapeutics Stock (NASDAQ:CDTX)Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.Read More CDTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CDTX Stock News HeadlinesMarch 13, 2024 | insidertrades.comInsider Selling: Cidara Therapeutics, Inc. (NASDAQ:CDTX) CFO Sells 18,931 Shares of StockMarch 17, 2024 | finance.yahoo.comCidara Therapeutics, Inc. (CDTX)March 28, 2024 | Behind the Markets (Ad)The AI Defense Stock Set to SoarTo protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.March 9, 2024 | edition.cnn.comCidara Therapeutics, Inc.March 6, 2024 | finance.yahoo.comCidara Therapeutics to Present Preclincal Data on Multiple Novel Drug-Fc Conjugate Candidates at American Association for Cancer Research (AACR) Annual Meeting 2024March 6, 2024 | globenewswire.comCidara Therapeutics to Present Preclincal Data on Multiple Novel Drug-Fc Conjugate Candidates at American Association dor Cancer Research (AACR) Annual Meeting 2024February 15, 2024 | finance.yahoo.comSteven Cohen's Point72 Adds Cidara Therapeutics to Its PortfolioFebruary 12, 2024 | msn.comCidara receives $11M milestone payment from partner MundipharmaMarch 28, 2024 | Crypto 101 Media (Ad)Crypto Market Preps For Trillions Worth of Inflows! Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.February 12, 2024 | marketwatch.comCidara Therapeutics Gets $11.1M Milestone Payment for RezzayoFebruary 12, 2024 | markets.businessinsider.comCidara Receives Milestone Payment From Mundipharma On European Approval Of REZZAYOFebruary 12, 2024 | finance.yahoo.comCidara Therapeutics Receives $11.14 Million Milestone Payment Following European Approval of REZZAYOFebruary 10, 2024 | markets.businessinsider.comCidara Therapeutics Granted Nasdaq Listing ExtensionJanuary 30, 2024 | finanznachrichten.deCidara Therapeutics, Inc.: Cidara Therapeutics Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in AdultsJanuary 30, 2024 | msn.comPalatin to raise ~$10M via securities offeringJanuary 29, 2024 | marketwatch.comCidara Therapeutics Gets UK Watchdog's Approval for Invasive Candidiasis TreatmentJanuary 29, 2024 | marketwatch.comCidara Therapeutics Shares Up 14% After UK Approval of Invasive Candidiasis Infection TreatmentJanuary 29, 2024 | msn.comCidara rallies 13% after hours on UK approval for RezzayoJanuary 29, 2024 | finance.yahoo.comCidara Therapeutics Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in AdultsDecember 22, 2023 | markets.businessinsider.comCidara Therapeutics : EU Approves Rezzayo For Treatment Of Invasive Candidiasis In AdultsDecember 22, 2023 | finance.yahoo.comCidara Therapeutics Announces European Approval of REZZAYO® (rezafungin) for the Treatment of Invasive Candidiasis in AdultsDecember 21, 2023 | benzinga.comCidara Therapeutics Stock (NASDAQ:CDTX) Dividends: History, Yield and DatesDecember 7, 2023 | finance.yahoo.comCidara Therapeutics Presents New Promising Preclincal Data on Novel Dual-Acting Drug-Fc Conjugates at ESMO Immuno-Oncology Annual CongressDecember 6, 2023 | finance.yahoo.comCidara Therapeutics Announces Completion of Enrollment in Phase 3 Restore Trial of Rezafungin in ChinaNovember 30, 2023 | finance.yahoo.comCidara Therapeutics to Present New Preclinical Data on Novel Dual-Acting Drug-Fc Conjugates at ESMO Immuno-Oncology Annual CongressNovember 20, 2023 | finance.yahoo.comCidara Therapeutics Named as a San Diego Metro Area Top WorkplaceNovember 4, 2023 | benzinga.comCidara Therapeutics Presents Preclinical Data on Novel Drug-Fc Conjugate CBO421 at SITC's 38ᵗʰ Annual MeetingSee More Headlines Receive CDTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cidara Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today3/28/2024Next Earnings (Estimated)3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:CDTX CUSIPN/A CIK1610618 Webwww.cidara.com Phone(858) 752-6170FaxN/AEmployees73Year FoundedN/APrice Target and Rating Average Stock Price Target$4.67 High Stock Price Target$6.00 Low Stock Price Target$3.00 Potential Upside/Downside+454.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-29,800,000.00 Net Margins-55.49% Pretax Margin-53.14% Return on Equity-264.84% Return on Assets-48.12% Debt Debt-to-Equity RatioN/A Current Ratio1.62 Quick Ratio1.55 Sales & Book Value Annual Sales$64.29 million Price / Sales1.19 Cash FlowN/A Price / Cash FlowN/A Book Value($0.04) per share Price / Book-21.05Miscellaneous Outstanding Shares90,620,000Free Float83,886,000Market Cap$76.31 million OptionableOptionable Beta0.95 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Jeffrey L. Stein Ph.D. (Age 69)President, CEO & Executive Director Comp: $873.25kDr. Preetam Shah M.B.A. (Age 51)Ph.D., CFO, Chief Business Officer & Principal Accounting Officer Comp: $577.85kDr. Taylor Sandison (Age 52)Chief Medical Officer Comp: $632.05kDr. Kevin M. Forrest Ph.D. (Age 47)Founder and Chief Strategy Officer Comp: $333.31kMr. Shane M. Ward (Age 49)COO & Chief Legal Officer Ms. Allison Lewis CCPSPHR, Senior Vice President of People & CultureDr. Leslie Tari Ph.D. (Age 57)Chief Scientific Officer Comp: $845.1kMs. Laura A. NavaltaSenior Vice President of Clinical OperationsDr. Nicole Davarpanah J.D.M.D., Senior VP of Translational Research & DevelopmentMore ExecutivesKey CompetitorsInflaRxNASDAQ:IFRXLeap TherapeuticsNASDAQ:LPTXRegulus TherapeuticsNASDAQ:RGLSCorvus PharmaceuticalsNASDAQ:CRVSCellectar BiosciencesNASDAQ:CLRBView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 54,310 shares on 3/11/2024Ownership: 3.693%Leslie TariSold 21,029 sharesTotal: $14,089.43 ($0.67/share)Preetam ShahSold 18,931 sharesTotal: $12,683.77 ($0.67/share)Shane WardSold 20,473 sharesTotal: $13,716.91 ($0.67/share)Virtu Financial LLCBought 76,386 shares on 2/26/2024Ownership: 0.106%View All Insider TransactionsView All Institutional Transactions CDTX Stock Analysis - Frequently Asked Questions Should I buy or sell Cidara Therapeutics stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cidara Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CDTX shares. View CDTX analyst ratings or view top-rated stocks. What is Cidara Therapeutics' stock price target for 2024? 3 Wall Street research analysts have issued 1 year price objectives for Cidara Therapeutics' shares. Their CDTX share price targets range from $3.00 to $6.00. On average, they predict the company's stock price to reach $4.67 in the next twelve months. This suggests a possible upside of 454.2% from the stock's current price. View analysts price targets for CDTX or view top-rated stocks among Wall Street analysts. How have CDTX shares performed in 2024? Cidara Therapeutics' stock was trading at $0.7940 at the beginning of 2024. Since then, CDTX shares have increased by 6.1% and is now trading at $0.8421. View the best growth stocks for 2024 here. Are investors shorting Cidara Therapeutics? Cidara Therapeutics saw a decrease in short interest in March. As of March 15th, there was short interest totaling 179,500 shares, a decrease of 18.9% from the February 29th total of 221,400 shares. Based on an average daily trading volume, of 713,100 shares, the short-interest ratio is presently 0.3 days. View Cidara Therapeutics' Short Interest. When is Cidara Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024. View our CDTX earnings forecast. How were Cidara Therapeutics' earnings last quarter? Cidara Therapeutics, Inc. (NASDAQ:CDTX) announced its quarterly earnings results on Wednesday, November, 10th. The biotechnology company reported ($0.37) earnings per share for the quarter, missing analysts' consensus estimates of ($0.36) by $0.01. The biotechnology company earned $7.08 million during the quarter, compared to the consensus estimate of $3.62 million. Cidara Therapeutics had a negative trailing twelve-month return on equity of 264.84% and a negative net margin of 55.49%. What other stocks do shareholders of Cidara Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cidara Therapeutics investors own include Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Verastem (VSTM), Dynavax Technologies (DVAX), Micron Technology (MU), Exelixis (EXEL), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE) and Catalyst Pharmaceuticals (CPRX). When did Cidara Therapeutics IPO? Cidara Therapeutics (CDTX) raised $60 million in an IPO on Wednesday, April 15th 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Jefferies and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow Life Sciences, Needham and BTIG were co-managers. Who are Cidara Therapeutics' major shareholders? Cidara Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (3.70%), Vanguard Group Inc. (3.69%), Nantahala Capital Management LLC (1.71%), GSA Capital Partners LLP (0.60%), Northern Trust Corp (0.18%) and Virtu Financial LLC (0.11%). Insiders that own company stock include Brady Johnson, Jeffrey Stein, Jessica Oien, Leslie Tari, Neil Abdollahian, Paul Daruwala, Preetam Shah, Shane Ward, Taylor Sandison and Timothy R Franson. View institutional ownership trends. How do I buy shares of Cidara Therapeutics? Shares of CDTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CDTX) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the Markets“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThe 3rd Revolution in WarfareWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cidara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.